Loading
Boston sarcoma doctor who first showed that mTOR inhibitors shrink perivascular epithelioid cell tumours and then led AMPECT, the trial that made nab-sirolimus the first approved treatment for these rare cancers.
Andrew Wagner is a medical oncologist in the sarcoma centre at Dana-Farber Cancer Institute. He was first author of the 2010 Journal of Clinical Oncology report showing responses to sirolimus in malignant perivascular epithelioid cell tumours, linking their TSC1/TSC2 loss to mTOR dependence, and of the 2021 Journal of Clinical Oncology report of AMPECT, the phase 2 trial in which nab-sirolimus produced durable responses in advanced malignant PEComa, the basis of the first approval for the disease.
| Title | Journal | Year |
|---|---|---|
| AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours | Journal of Clinical Oncology | 2021 |
| Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours | Journal of Clinical Oncology | 2010 |
Nab-sirolimus is the approved first-line treatment for advanced malignant PEComa, and TSC1/TSC2 testing helps predict response.
mTOR inhibition became the therapeutic strategy for PEComa, culminating in the AMPECT trial and approval of nab-sirolimus.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, rare-cancers, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours, Perivascular epithelioid cell tumour (PEComa), Sarcomas (soft tissue, bone, GIST).
Shares Dana-Farber Brigham Cancer Center, Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, targeted-therapy.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.
Shares Sarcomas (soft tissue, bone, GIST) and the tags sarcoma, trialist.